Literature DB >> 19582562

The analysis of tryptase in serum of sarcoidosis patients.

Elena Bargagli1, Angela Mazzi, Fabrizio Mezzasalma, Anna Perrone, Carmela Olivieri, Antje Prasse, Nicola Bianchi, Maria G Pieroni, Paola Rottoli.   

Abstract

Sarcoidosis is a systemic granulomatous disease of unknown etiology characterized by activation of macrophages and T lymphocytes. Relatively little is known about the role of mast cells and their mediators in the pathogenesis of sarcoidosis. Tryptase is an enzyme produced by activated mast cells, regarded as a marker of mast cell activation. To analyse tryptase concentrations in serum of sarcoidosis patients in an attempt to define the role of tryptase and mast cells in the pathogenesis of sarcoidosis and to evaluate the potential of tryptase as marker of disease severity. Quantitative analysis of tryptase concentrations was performed in serum of patients with stable sarcoidosis (n = 12), progressive sarcoidosis (n = 23) and controls (n = 13). Patients enrolled in the study had been monitored at Siena Regional Referral Centre for Sarcoidosis from onset for at least 12 months. Significantly higher concentrations of tryptase were found in peripheral blood of sarcoidosis patients (6.08 +/- 3.98 microg/l) than controls (2.96 +/- 1.75microg/l; p = 0.012). Patients with progressive disease showed the highest tryptase concentrations in serum. Tryptase and mast cells may be involved in the immunopathogenesis of sarcoidosis and further studies are required to understand if tryptase may represent a marker of sarcoidosis severity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582562     DOI: 10.1007/s10753-009-9137-z

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  33 in total

1.  Mast cell tryptases and airway remodeling.

Authors:  C P Sommerhoff
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

2.  Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis.

Authors:  M W Ziegenhagen; M E Rothe; M Schlaak; J Müller-Quernheim
Journal:  Eur Respir J       Date:  2003-03       Impact factor: 16.671

Review 3.  Tryptase genetics and anaphylaxis.

Authors:  George H Caughey
Journal:  J Allergy Clin Immunol       Date:  2006-04-27       Impact factor: 10.793

4.  [The clinical significance of mast cell tryptase in bronchial alveolar lavage fluid in interstitial lung diseases].

Authors:  Kiyomi Kawatani; Mitsuko Kondo; Jun Tamaoki; Etsuko Tagaya; Atsushi Nagai
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2007-11

5.  Mast cells in the rat alveolar septa undergoing fibrosis after ionizing irradiation. Ultrastructural and histochemical studies.

Authors:  S Watanabe; K Watanabe; T Oishi; M Aiba; K Kageyama
Journal:  Lab Invest       Date:  1974-11       Impact factor: 5.662

6.  Mast cells in the cutaneous lesions of sarcoidosis: their subtypes and the relationship to systemic manifestations.

Authors:  H Amano; M Kurosawa; O Ishikawa; J Chihara; Y Miyachi
Journal:  J Dermatol Sci       Date:  2000-09       Impact factor: 4.563

7.  Outcome of the treatment for sarcoidosis.

Authors:  G W Hunninghake; S Gilbert; R Pueringer; C Dayton; C Floerchinger; R Helmers; R Merchant; J Wilson; J Galvin; D Schwartz
Journal:  Am J Respir Crit Care Med       Date:  1994-04       Impact factor: 21.405

8.  Sarcoidosis patients have bronchial hyperreactivity and signs of mast cell activation in their bronchoalveolar lavage.

Authors:  M B Ohrn; C M Sköld; M van Hage-Hamsten; O Sigurdardottir; O Zetterström; A Eklund
Journal:  Respiration       Date:  1995       Impact factor: 3.580

9.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity.

Authors:  G W Hunninghake; R G Crystal
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

Review 10.  Is bronchoalveolar lavage obsolete in the diagnosis of interstitial lung disease?

Authors:  Paola Rottoli; Elena Bargagli
Journal:  Curr Opin Pulm Med       Date:  2003-09       Impact factor: 3.155

View more
  6 in total

Review 1.  The puzzling clinical spectrum and course of juvenile sarcoidosis.

Authors:  Andrew Fretzayas; Maria Moustaki; Olga Vougiouka
Journal:  World J Pediatr       Date:  2011-05-15       Impact factor: 2.764

2.  Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers.

Authors:  Gregorino Paone; Alvaro Leone; Sandro Batzella; Vittoria Conti; Francesco Belli; Laura De Marchis; Alice Mannocci; Giovanni Schmid; Claudio Terzano
Journal:  Inflamm Res       Date:  2012-12-23       Impact factor: 4.575

3.  Cathepsin S, a new serum biomarker of sarcoidosis discovered by transcriptome analysis of alveolar macrophages.

Authors:  Hiroyuki Tanaka; Etsuro Yamaguchi; Nobuhiro Asai; Toyoharu Yokoi; Masaki Nishimura; Haruhisa Nakao; Masashi Yoneda; Yoshinori Ohtsuka; Satoshi Konno; Noritaka Yamada
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

4.  PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells.

Authors:  Jan Beute; Keerthana Ganesh; Hedwika Nastiti; Robin Hoogenboom; Vivica Bos; Jelle Folkerts; Marco W J Schreurs; Steve Hockman; Rudi W Hendriks; Alex KleinJan
Journal:  Front Pharmacol       Date:  2020-05-01       Impact factor: 5.810

Review 5.  Catch the rainbow: Prognostic factor of sarcoidosis.

Authors:  Senol Kobak
Journal:  Lung India       Date:  2020 Sep-Oct

6.  Clinical phenotyping in sarcoidosis management.

Authors:  Giuseppe Domenico Rana; Miriana d'Alessandro; Luigi Rizzi; Laura Bergantini; Paolo Cameli; Alfredo Vozza; Piersante Sestini; Patrizia Suppressa; Elena Bargagli
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2021-06-28       Impact factor: 0.670

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.